Company Profile

TearLab Corporation is an in-vitro diagnostic company. The Company has commercialized a tear testing platform, the TearLab Osmolarity System, which enables eye care practitioners to test for sensitive and specific biomarkers using nanoliters of tear film at the point-of-care. The Company, through its subsidiary TearLab Research, Inc., develops technologies to enable eye care practitioners to test a range of biomarkers (chemistries, metabolites, genes and proteins) at the point-of-care. Its product, the TearLab Osmolarity System, enables the measurement of tear osmolarity in the doctor's office. The TearLab Osmolarity System consists of approximately three components: the TearLab disposable, the TearLab Pen, and the TearLab Reader. The TearLab disposable is a single-use microfluidic microchip. The TearLab Pen is a hand-held device that interfaces with the TearLab disposable. The TearLab Reader is a small desktop unit that allows for the docking of the TearLab Pen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.	CI
09/12/21	TearLab Corporation Announces Board Appointments	CI
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer	CI
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors	CI
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans	CI
28/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer	CI
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.	CI
09/07/20	TearLab Corporation to Seek Acquisitions	CI
26/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020	CI
11/05/20	TearLab Corporation Announces Board Appointments	CI
11/05/20	Tearlab Mulls Inorganic Growth Opportunities	CI
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund	CI
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.	CI

09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
26/06/20	TearLab: 1Q Earnings Snapshot	AQ
26/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)	AQ
09/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)	AQ
30/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)	AQ

Manager	Title	Age	Since
Benjamin D. Sullivan CTO	Chief Tech/Sci/R&D Officer	-	17/07/2009
Adam Szaronos CEO	Chief Executive Officer	-	01/04/2026
John Lund DFI	Director of Finance/CFO	60	01/07/2022

Director	Title	Age	Since
Uri Geiger BRD	Director/Board Member	58	09/07/2020
James V. Mazzo CHM	Chairman	68	09/12/2021
Richard Lindstrom BRD	Director/Board Member	78	01/09/2004

TearLab Corp Stock OTC Bulletin Board

Stocks

Medical Equipment, Supplies & Distribution

Latest news : TearLab Corp

Press Releases: TearLab Corp

Managers and Directors: TearLab Corp

Glasses, Spectacles & Contact Lenses

Company Profile

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ESSILORLUXOTTICA	-0.23%	+3.91%	-27.08%	+1.23%	90.58B
ALCON INC.	+0.39%	-3.19%	-23.89%	-25.59%	32.45B
THE COOPER COMPANIES, INC.	+0.33%	+4.53%	-1.18%	-24.94%	14.03B
LENSKART SOLUTIONS LIMITED	-0.03%	+4.22%	-	-	9.69B
SHANGHAI CONANT OPTICAL CO., LTD.	+2.48%	-2.31%	-13.32%	+516.86%	1.95B
AUTEK CHINA INC.	+3.89%	+0.74%	-28.68%	-63.76%	1.44B
PEGAVISION CORPORATION	-1.45%	+4.29%	+12.21%	-1.45%	819M
MINGYUE OPTICAL LENS CO.,LTD.	+3.85%	+1.04%	-41.20%	-31.05%	836M
MENICON CO., LTD.	+1.57%	-1.24%	+48.32%	-33.57%	755M
Average	+1.20%	+0.49%	-9.35%	+42.22%	16.95B
Weighted average by Cap.	+0.06%	+1.44%	-23.10%	-1.45%